结直肠癌治疗反应的民族多样性:放射组学驱动富集试验的概念验证
本研究回顾性分析两项III期试验中1584例转移性结直肠癌患者的CT图像,评估放射组学特征预测总生存能否揭示民族与疗效的关联。结果显示民族与治疗反应相关,拉丁裔患者第2个月RECIST1.1缓解率较高(55.6%),肿瘤体积变化和放射组学异质性在不同民族间也存在差异。
要点
- 民族与第2个月RECIST1.1缓解相关(p=0.048),拉丁裔患者缓解率较高(55.6%)。
- 拉丁裔患者第2个月肿瘤体积变化更可能提示治疗反应(p=0.021)。
- 肿瘤放射组学异质性在不同民族间存在差异(p=0.023)。
核心结论
- 民族与转移性结直肠癌治疗反应相关;在样本量足够的研究中,放射组学特征可能有助于揭示民族与疗效的关联、阐明耐药机制并通过预测性富集促进试验多样性。
研究设计与样本
- 回顾性分析两项III期试验的CT图像,共纳入1584例转移性结直肠癌患者,评估FOLFOX±帕尼单抗(n=331,350)和FOLFIRI±阿柏西普(n=437,466),图像采集时间为2006年8月至2013年3月。
诊断标准与关键数值
- 主要终点为第2个月RECIST1.1缓解,次要终点为第2个月肿瘤体积变化。
- 辅助研究使用结合3个影像特征的同行评议放射组学特征预测从第2个月起算的总生存。
- 民族与第2个月RECIST1.1缓解相关(p=0.048),拉丁裔缓解率较高(55.6%)。
- 拉丁裔患者第2个月肿瘤体积变化更可能提示治疗反应(p=0.021)。
- 肿瘤放射组学异质性在不同民族间存在差异(p=0.023)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND: Several barriers hamper recruitment of diverse patient populations in multicenter clinical trials which determine efficacy of new systemic cancer therapies.
PURPOSE: We assessed if quantitative analysis of computed tomography (CT) scans of metastatic colorectal cancer (mCRC) patients using imaging features that predict overall survival (OS) can unravel the association between ethnicity and efficacy.
METHODS: We retrospectively analyzed CT images from 1584 mCRC patients in two phase III trials evaluating FOLFOX ± panitumumab (n = 331, 350) and FOLFIRI ± aflibercept (n = 437, 466) collected from August 2006 to March 2013. Primary and secondary endpoints compared RECIST1.1 response at month-2 and delta tumor volume at month-2, respectively. An ancillary study compared imaging phenotype using a peer-reviewed radiomics-signature combining 3 imaging features to predict OS landmarked from month-2. Analysis was stratified by ethnicity.
RESULTS: In total, 1584 patients were included (mean age, 60.25 ± 10.57 years; 969 men). Ethnicity was as follows: African (n = 50, 3.2%), Asian (n = 66, 4.2%), Caucasian (n = 1413, 89.2%), Latino (n = 27, 1.7%), Other (n = 28, 1.8%). Overall baseline tumor volume demonstrated Africans and Caucasians had more advanced disease (p < 0.001). Ethnicity was associated with treatment response. Response per RECIST1.1 at month-2 was distinct between ethnicities (p = 0.048) with higher response rate (55.6%) in Latinos. Overall delta tumor volume at month-2 demonstrated that Latino patients more likely experienced response to treatment (p = 0.021). Radiomics phenotype was also distinct in terms of tumor radiomics heterogeneity (p = 0.023).
CONCLUSION: This study highlights how clinical trials that inadequately represent minority groups may impact associated translational work. In appropriately powered studies, radiomics features may allow us to unravel associations between ethnicity and treatment efficacy, better elucidate mechanisms of resistance, and promote diversity in trials through predictive enrichment.
CLINICAL RELEVANCE STATEMENT: Radiomics could promote clinical trial diversity through predictive enrichment, hence benefit to historically underrepresented racial/ethnic groups that may respond variably to treatment due to socioeconomic factors and built environment, collectively referred to as social determinants of health.
KEY POINTS: •Findings indicate ethnicity was associated with treatment response across all 3 endpoints. First, response per RECIST1.1 at month-2 was distinct between ethnicities (p = 0.048) with higher response rate (55.6%) in Latinos. •Second, the overall delta tumor volume at month-2 demonstrated that Latino patients were more likely to experience response to treatment (p = 0.021). Radiomics phenotype was also distinct in terms of tumor radiomics heterogeneity (p = 0.023).
引用
- Dercle, Yang, Gönen, et al. Ethnic diversity in treatment response for colorectal cancer: proof of concept for radiomics-driven enrichment trials. Eur Radiol. 2023. PMID: 37368111. doi:10.1007/s00330-023-09862-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。